This is an existential threat to Cardiff's business model. Monitor court filings for preliminary injunction rulings and any settlement discussions. A prolonged legal battle with uncertain IP ownership will likely pressure the stock significantly.
Price Chart
Executive Summary
Cardiff Oncology disclosed that its licensor, Nerviano Medical Sciences (NMS), has terminated the key license agreement for onvansertib, alleging material breach. Cardiff disputes the termination and has an active lawsuit against NMS. This threatens the company's core asset and pipeline.
Key Facts
- On May 27, 2026, NMS notified Cardiff it was terminating the License Agreement dated March 13, 2017, alleging material breach.
- NMS claims Cardiff failed to name an NMS employee as joint inventor on two patents and failed to use commercially reasonable efforts to develop onvansertib.
- Cardiff filed a lawsuit on May 19, 2026, seeking injunctive relief and a declaratory judgment that it did not breach the agreement.
- Cardiff responded that the termination notice is legally ineffective and will continue to perform under the agreement.
- Onvansertib is Cardiff's only clinical-stage asset; loss of the license would be existential.
Financial Impact
Loss of license for onvansertib, the company's sole pipeline drug, could render the company worthless. No financial terms of the license were disclosed.
Risk Factors
- Loss of the license for onvansertib would eliminate the company's only clinical asset.
- Adverse court ruling could force Cardiff to cease development or pay substantial damages.
- Potential for further litigation costs and management distraction.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-248711 |
| Document: 0001193125-26-248711-index-headers.html | 0001193125-26-248711 |
| Document: 0001193125-26-248711-index.html | 0001193125-26-248711 |
| Document: 0001193125-26-248711.txt | 0001193125-26-248711 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 22, 2026 4w ago | Institutional Cluster | $1.33 $1.17 | ▲ +12.03% | ▲ +10.84% | $0.8400 (+36.84%) |
Sep 14, 2026 6w ago | 8-K | $1.31 $1.37 | ▲ +4.58% | ▲ +4.47% | $0.8400 (−35.88%) |
Aug 11, 2026 10w ago | Press Release | $0.9900 $0.8979 | ▲ +9.30% | ▲ +8.86% | $0.8400 (+15.15%) |
Jul 16, 2026 14w ago | Insider Cluster | $0.8800 $0.8381 | ▼ −4.76% | ▼ −4.07% | $0.8400 (−4.55%) |
Jul 16, 2026 14w ago | 8-K | $0.8745 $0.8381 | ▲ +4.16% | ▲ +2.49% | $0.8400 (+3.95%) |
Jul 16, 2026 14w ago | 424B5 | $0.8745 $0.8381 | ▲ +4.16% | ▲ +2.49% | $0.8400 (+3.95%) |
Jun 22, 2026 18w ago | Insider Cluster | $1.30 $1.25 | ▼ −3.85% | ▼ −1.78% | $0.8400 (−35.38%) |
Jun 11, 2026 19w ago | Institutional Cluster | $1.59 $1.18 | ▲ +25.79% | ▲ +26.22% | $0.8400 (+47.17%) |
Jun 3, 2026 20w ago | 8-K | $1.40 $1.48 | ▲ +5.71% | ▲ +9.53% | $0.8400 (−40.00%) |
Jun 2, 2026 21w ago | Press Release | $1.51 $1.53 | ▲ +1.32% | ▲ +4.29% | $0.8400 (−44.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers